Answer
Edarbi is converted to azilsartan, which lowers blood pressure by blocking angiotensin II from binding to AT1 receptors, counteracting effects including blood vessel constriction, aldosterone release and kidney sodium reabsorption.
Sources for this answer
- Edarbi TabletsTakeda UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 12Document updated
Sources checked